# Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

> **NCT05747521** · NA · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 85 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Anrotinib hydrochloride combined with adriamycin

## Key facts

- **NCT ID:** NCT05747521
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-29
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05747521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05747521, "Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05747521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*